|

Imlunestrant Clinical Trials

4 actively recruiting trials across 3 locations

▲ +1 trial since August 2026

Also known as: Inluriyo, LY 3484356, LY-3484356, LY3484356, SERD LY3484356 +1 more

Pipeline

Phase 1: 1Phase 2: 2Phase 1/2: 1

Top Sponsors

  • Eli Lilly and Company3
  • Jonsson Comprehensive Cancer Center1

Indications

  • Breast Cancer4
  • Cancer4
  • Localized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast Carcinoma1
  • Localized Estrogen Receptor-Positive Breast Carcinoma1
  • Solid Tumors, Adult1

Los Angeles, California2 trials

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Ellison Clinic at Saint John's

Phase 1/2
Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

UCLA / Jonsson Comprehensive Cancer Center

Phase 2

Birmingham, Alabama1 trial

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

University of Alabama at Birmingham

Phase 2

Scottsdale, Arizona1 trial

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

Mayo Clinic of Scottsdale

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.